title: The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer.
abstract: OBJECTIVE
  Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors.
  
  
  METHODS
  The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay.
  
  
  RESULTS
  No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p=0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p=1.75(-9)). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%.
  
  
  CONCLUSIONS
  G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.
authors.affiliation: Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Borgmann
authors.forename: Annette
authors.initials: A
authors.lastname: Raabe
authors.forename: Sebastian
authors.initials: S
authors.lastname: Reuther
authors.forename: Silke
authors.initials: S
authors.lastname: Szymczak
authors.forename: Thorsten
authors.initials: T
authors.lastname: Schlomm
authors.forename: Hendrik
authors.initials: H
authors.lastname: Isbarn
authors.forename: Maria
authors.initials: M
authors.lastname: Gomolka
authors.forename: Andreas
authors.initials: A
authors.lastname: Busjahn
authors.forename: Michael
authors.initials: M
authors.lastname: Bonin
authors.forename: Andreas
authors.initials: A
authors.lastname: Ziegler
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Dikomey
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D016022:Case-Control Studies; D002877:Chromosomes, Human / Q000528:radiation effects*; D016001:Confidence Intervals; D016195:G2 Phase / Q000235:genetics / Q000528:radiation effects*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy; D011836:Radiation Tolerance / Q000235:genetics*; D012016:Reference Values; D016192:Resting Phase, Cell Cycle / Q000235:genetics / Q000528:radiation effects*; D018570:Risk Assessment